Sionna Therapeutics (SION) Interest Coverage Ratio: History & Chart

Sionna Therapeutics, Inc.(SION)

Biotechnology · Waltham, MA

$4.69-0.17 (-3.40%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

About Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Waltham, MA

59 employees

www.sionnatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Cloonan

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Sionna Therapeutics, Inc. (SION)	$211.53M	N/A	N/A	N/A	N/A
Niagen Bioscience Inc (NAGE)vs ›	$214.24M	N/A	N/A	N/A	N/A
Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›	$215.07M	N/A	1274.61x	1274.61x	1274.61x
Compugen Ltd. (CGEN)vs ›	$209.91M	N/A	39.15x	39.15x	39.15x
Lyell Immunopharma, Inc. (LYEL)vs ›	$210.98M	N/A	N/A	N/A	N/A
Entrada Therapeutics, Inc. (TRDA)vs ›	$209.68M	N/A	N/A	N/A	N/A
Pro-Dex, Inc. (PDEX)vs ›	$207.27M	16.00x	14.45x	13.14x	13.02x
Prelude Therapeutics Incorporated (PRLD)vs ›	$216.91M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$208.31M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$218.30M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Sionna Therapeutics, Inc. (SION)

$211.53M

N/A

Niagen Bioscience Inc (NAGE)vs ›

$214.24M

N/A

Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›

$215.07M